Semax vs Noopept

The distinction that mattersBoth Russian nootropics sold as Western supplements. Semax is an intranasal ACTH fragment; noopept is an orally active dipeptide ester that FDA has ruled is not a lawful dietary ingredient.

	Semax Limited Approval	Noopept Limited Approval
Evidence rating	2/5 Limited Evidence rating 2 out of 5: Limited	2/5 Limited Evidence rating 2 out of 5: Limited
Regulatory status	Registered in Russia for stroke, cognitive disorders and optic nerve conditions. Not approved in the US, EU or UK.	Registered as a prescription medicine in Russia. In the US, FDA has determined it is not a lawful dietary ingredient. Not approved in the EU or UK.
Category	Cognitive & Neurological	Cognitive & Neurological
Drug class	Synthetic heptapeptide analog of ACTH (4-10) with no corticotropic activity	Dipeptide-derived nootropic — a proline-containing dipeptide ethyl ester
Route	Intranasal (primary), subcutaneous	Oral or sublingual
Half-life	Minutes systemically; central effects outlast plasma levels	~16–30 minutes (active metabolite cycloprolylglycine persists longer)
Studied in	Russian clinical trials in ischemic stroke, cognitive impairment, optic nerve atrophy and ADHD; extensive Russian preclinical neuroprotection work.	Russian randomized trials in mild cognitive impairment of vascular and post-traumatic origin; extensive Russian preclinical work.
Who should avoid it	Pregnancy Uncontrolled anxiety disorders Concurrent stimulant use without medical supervision	Pregnancy and breastfeeding Uncontrolled hypertension Severe hepatic or renal impairment Concurrent stimulants without medical supervision
Legal status	Prescription medicine in Russia. Unapproved elsewhere; import for personal use occupies a legal grey area.	Prescription medicine in Russia. Not a lawful dietary supplement in the US. Unapproved in the EU and UK.

Benefits — Semax

Neuroprotection in stroke models
Consistent reduction in infarct volume and improved functional recovery in animal ischemia models, supported by Russian clinical use.
BDNF upregulation
Documented increases in brain-derived neurotrophic factor expression, a plausible substrate for cognitive effects.
Reported attention and memory effects
Russian studies and extensive user reports describe improved focus and working memory; not replicated under Western trial conditions.
No corticotropic activity
Unlike ACTH itself, it does not stimulate cortisol release — an important safety feature.
Good short-term tolerability
Decades of Russian clinical use without major safety signals reported.

Benefits — Noopept

Reported cognitive benefit in mild impairment
Russian randomized trials described improvement in cognitive and affective symptoms in vascular and post-traumatic cognitive impairment.
Neurotrophin upregulation
Documented increases in hippocampal BDNF and NGF expression in animal models.
Active at low doses
Roughly a thousandfold more potent by weight than piracetam.
Anxiolytic component reported
Russian studies describe reduced anxiety and irritability alongside cognitive effects.

Risks & cons — Semax

No Western regulatory review
Not evaluated by FDA or EMA. The evidence base has not been independently audited.
Trial methodology concerns
Much of the supporting literature lacks blinding, adequate power, or placebo control by contemporary standards.
Unknown long-term neurological effects
Chronically manipulating neurotrophin expression has no long-term human safety characterisation.
Grey-market supply in the West
Purity and concentration of imported product are unverified.
Overstimulation and irritability
Commonly reported at higher doses, along with headache and sleep disruption.

Risks & cons — Noopept

Not a lawful supplement in the US
FDA has stated it does not meet the dietary ingredient definition, making its sale as a supplement unlawful — a fact most vendors omit.
Evidence base not independently replicated
No Western randomized trials exist. Methodological standards in the source literature are inconsistent.
Irritability, headache and sleep disruption
Commonly reported, particularly at higher doses or later in the day.
Blood pressure elevation
Reported in some users; caution advised in hypertension.
No long-term safety data
Chronic use has not been characterised outside Russian practice.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.